Constitutional Re-Conditioning of Micro Environmental Induction of Malignant Progression in Melanoma Pathogenesis

Lawrence M Agius*
Department of Pathology, University of Malta Medical School, Malta

*Corresponding author: Lawrence M Agius, Department of Pathology, Mater Dei Hospital, Tal-Qroqq, University of Malta Medical School, Msida, Malta

Submission: July 13, 2018; Published: August 03, 2018

Abstract

Melanoma constitutes a primary focus of constitutional re-determination that foreshadows the dynamic profiles for pathway non-resolution as determined by pathologic delineation of clinical aggressiveness in growth and spread of the lesion. The significance of prognostic markers presently available do not reliably indicate the distinctive evolution of progression, as well-indicated by systems of targeting pathways and as genetic profile coordinates. These genetic profiles overwhelmingly give specific dimension to the significant evolutionary acquisition of attributes for non-resolution of the primary and metastatic lesions. It is further to such considerations that the identity profile for a given melanoma allow for emergence of projected systems of distinctive induction in terms that re-confirm the initial transformation event in groups of individual melanocytes.

Keywords: Melanoma; Constitutional; Microenvironment; Malignancy

Introduction

Melanoma constitutes malignant transformation of melanocytes that exhibit a considerable propensity for spread of, and also resistance to, chemotherapy response. In malignant melanoma both the BRAF/MEK/ERK and PI3-K/AKT signaling pathways are constitutively activated through multiple mechanisms, which result in cell cycle progression and prevention of apoptosis [1]. The inherent propensity for spread is relative to the accumulation of mutations and deletions in target pathways such as the MAPK and BRAF targeting events. This occurs in a manner that implicates the carcinogenesis in terms of multiple pathway outcomes within a highly heterogeneous group of melanoma neoplasms. Aspects implicate the Wnt/beta-catenin pathway-related epithelial-mesenchymal transition versus mesenchymal-epithelial transition of keratinocytes, fibroblasts and melanoma cells [2].

Significant to such dynamics is the proposed attempt at integration of such molecular pathways as RAS, RAF, PI3K, PTEN, that evolve in terms of indices of activity or suppression relative to the MAPK pathways. Incremental indices of constitutive over-activity implicate the emergence of pathway over-expression and targeting within systems for further growth of the malignant spread, radial growth spurt, and vertical growth phase that signify the system heterogeneity as borne out by the proposed targeting molecular systems. Unregulated FOXP1 is a new independent unfavorable prognosticator and a specific predictor of lymphatic dissemination in cutaneous melanoma patients; FOXP1 is implicated in B-cell development regulation and differentiation of monocytes, organ development and neuronal development [3].

System Tumor Biology

The overall system biology of melanoma depends, in many instances, on the presence of skin injury by ultraviolet light, as well-illustrated by the presence of solar elastosis in the surrounding skin. Macrophages form an inflammatory microenvironment that suppresses the immune system, stimulates angiogenesis, enhances migration and invasion and ultimately contributes to metastasis [4]. It is beyond such considerations that the system profile of constitutive and sporadic phenomena in transformation of melanocytes is closely allied to the propensity for early, aggressive spread of the malignant melanoma cells. A novel association exists between phenylalanine hydroxyls carrier status and melanoma risk [5]. Inclusive to such events is the dominant presence of mutations and deletions of MAPK. The accumulation of intermediate mediators, effecting over-activity of cyclin D1 and CDK4, thus reflects an oncogenesis within the system profiles of incremental oncogenesis, as further projected by the incorporated multi-pathway targeting in a serial mode of induced transformation of the melanocytes. Ultraviolet radiation directly induces DNA lesions and also impacts DNA repair proteins, the melanocyte microenvironment and DNA damage response [6].
The performance dynamics incorporate a malignant neoplasm that includes a biologic distinction between metastasizing versus non-metastasizing melanomas in terms of incremental targeting events as biologic entities. The cardiothoracic transplant population experiences an incidence of malignant melanoma similar to that of other solid organ transplant recipients [7]. Performance profiles are dynamic systems of attempted resolution in the first instance. Promoting susceptibilities in the face of invasive and metastasizing events implicate further growth of the melanocytes. Highly significant is the non-resolution of apoptosis and non-apoptosis within various systems of propagated indices such as degree of skin pigmentation, and re-characterization of emerging oncogenic pathways. Many melanomas present with a collective up-regulation of related H3K9 demethylase activities. Targeted inhibition restores senescence, even in Braf inhibitor-resistant melanomas, evoked secondary immune effects and controlled tumor growth in vivo [8,9].

**Potentiation of Induction**

Substantial potentiation of system progression is a significant pattern that involves the effective dimensions of constitutive transformation pathways of genetic identity and dysfunctionality. The overall creation of generative potential includes distributional oncogenic influence within the further targeting evolution for malignant progression in melanomas. Sir2un-1, a chromatin modifier, promotes Mxd1 silencing, which leads to increased activity of the MYC oncogene contributing to melanoma progression [10]. Turnover schemes for performance of malignancy include the re-conditioning of exposure to ultra-violet light in terms that also directly imply constitutive propensity for such promoted progression. Mechanistically, DOT1L histone H3 lysine 79 methyltransferase facilitates DNA damage repair with DOT1L-methylated H3K79 involvement in binding and recruiting XPC to the DNA damage site for nucleotide excision repair [11]. The vertical growth phase of melanomas has been utilized as measured index of prognostic import in further constitutive propensity for malignant change, with further progression of invasion and spread.

**Constitutional Attributes**

Constitutional pathogenesis of melanoma transformation includes the derivative phenomenon for progression of lesion malignancy as ongoing system profiles that are significant as performance indices. Shared pathways between human and Xiphophorus melanomas are related to inflammation, cell migration, cell proliferation, pigmentation, cancer development, and metastasis [12]. The distinction between radial spread and vertical spread phases incorporates distinctive parameters for attempts at prognostic determinations. It is with the view of a progressive malignant series of attributes that melanomas implicate transformation of genetic attributes on the one hand and system biology of signaling pathways that is influenced by micro-environmental conditioning and re-conditioning. Many immunomodulatory mechanisms, favouring melanoma genesis and progression, have been reported to interfere with melanoma recognition and immune cells response resulting in turn to immune resistance and immunosuppression [13]. Pathway attributes of induction further contribute to influential determination with constitutional conditioning of micro-environmental parameters of adaptive evolution, such as by Ultraviolet light radiation [14]. UVA1 might contribute to melanoma genesis as it partially inhibits the repair of UVB-induced cyclobutane pyrimidine dimers in human melanocytes while it does not affect UVB-mediated apoptosis [15]. Re-characterization is significant as proposed dimensions in the interplay dynamics of a growing lesion that is constitutively metastasizing at its inception and progression.

Overt dimensions for malignancy are distinct indices in the constitutive reframing of systems of determination, as well-projected by pathogenic abrogation and systemization of the evolving malignant melanocytes. MicroRNA expression plays a crucial role in melanoma cell proliferation, migration, and invasion, as well as miRNAs involved in apoptosis and in the immune response [16].

**Malignant Spread**

Attributes of malignant spread are aspects of an induction phenomenon that incorporates attributes of a constitutional origin within transforming melanocytes. Melanoma genesis depends on cells with the phenotype of progenitor cells expressing nestin, CD-133 or CD-271. Patient survival is potentially dependent on the neural crest stem cell transcription factor SOX10 [17]. In terms of incremental pathogenesis, the dynamics of performance profiles are clinical dimensional attributes of parametric significance, as testified by the emergence of an invasive front. Further to the metastasizing attributes for further progression, the stem cell constitution is distinctive parameter for index formulation in clinical outcome in the melanoma patient.

Overall assessment incrementally coordinates an evolutionary development of stem cell participation, as significantly denoted by system biology principles. The general re-characterization of malignant transformation promotes the emergence of proposed induction phenomena. Tumor-Sequencing studies have shown the widespread genetic diversity of melanomas [18]. It is further to such progression that constitutive dynamics call into operative dimension the projected attributes for spread. This is dictated by constitutionally conditioned indices of micro-environmental reconditioning of the lesion. MicroRNAs expression is a crucial player in modulating the key pathways that affect neocarcinogenesis, cancer progression and therapies [19].

**Concluding Remarks**

Dimensions of non-resolution conform to the appraisal modulators of a constitutional set of attributes within the array of performance properties inherent to constitutional events. This is evidenced by stem cell participation in carcinogenesis. Melanocyte stem cell activation and translocation initiate cutaneous melanoma in response to ultraviolet light exposure [20]. Distinctive parameters that contrast with the spread and metastatic growth...
of the melanoma are typified dimensions portrayed by dimensions of non-resolution. The evolutionary spectrum for spread is indeed the paramount attribute of a lesion that is inherently determined by distinct attributes of constitutional conditioning of micro-environmental parameters of progressive clinical and pathologic aggressiveness, the mutual inter-conditioning of micro-environment by malignant transformation emphasizes the instituted dimensions as constitutive attributes of a melanoma lesion. In vivo evidence indicates that differentiated somatic cells can be reprogrammed into cancer initiating cells [21]. This lesion spreads early in its growth phase and is further formulated by systems of tumor cell division and growth. Redistributed pathogenic factors operate for further progression as metastatic disease.

References

1. Zhang T, Wang Q, Fredimoses M, Gao G, Wang K, et al. (2018) The Ashitaba (Angelica keiskei) chalcones 4-hydroxyderricin and xanthoangelol suppress melanoma genesis by targeting BRAF and PI3-K. Cancer Prev Res (Phila) DOI: 10.1158.

2. Gurzu S, Belea MA, Jung I (2018) The role of tumor microenvironment in development and progression of malignant melanomas-a systematic review. Rom J Morphol Embryol 59(1): 23-28.

3. Donizy P, Pagacz K, Marczuk J, Fendler W, Maciejczyk A, et al. (2018) Up-regulation of FOXP1 is a new independent unfavourable prognosticator and a specific predictor of lymphatic dissemination in cutaneous melanoma patients. Onco Targets Ther 11: 1413-1422.

4. Pieniazek M, Matkowski R, Donizy P (2018) Macrophages in skin melanoma-the key element in melanoma genesis. Oncol Lett 15(4): 5399-5404.

5. Arbesman J, Ravichandran S, Funchain P, Thompson CL (2018) Melanoma cases demonstrate increased carrier frequency of phenylketonuria/hyperphenylalaninemia mutations. Pigment Cell Melanoma Res 31(4): 529-533.

6. Khan AQ, Travers JB, Kemp MG (2018) Roles of UVA radiation and DNA damage responses in melanoma pathogenesis. Environ Mol Mutagen 59(5): 438-460.

7. Puza CJ, Cardones AR, Mosca PJ (2018) Examining the incidence and presentation of melanoma in the cardiothoracic transplant population. JAMA Dermatol 154(5): 589-591.

8. Yu Y, Schleich K, Yue B, Ji S, Lohneis P, et al. (2018) Targeting the senescence-overriding cooperative activity of structurally unrelated H3K9 demethylases in melanoma. Cancer Cell 33(2): 322-336.

9. Wagner V, Gil J (2018) An epigenetic switch: from senescent melanocytes to malignant melanoma (and back). Cancer Cell 33(2): 162-163.

10. Melino FM, Micali D, Silva CT, Sabedot TS, Coetzee SG, et al. (2017) SIRT1 regulates Msd1 during malignant melanoma progression. Oncotarget 8(70): 114540-114553.

11. Zhu B, Chen S, Wang H, Yin C, Han C, et al. (2018) The protective role of DOT1L in UV-induced melanoma genesis. Nat Commun 9(1): 259.

12. Lu Y, Boswell M, Boswell W, Knetsch S, Hausmann M, et al. (2018) Comparison of Xiphophorus and Human melanoma transcriptomes reveals conserved pathway interactions. Pigment Cell Melanoma Res 31(4): 496-508.

13. Passreelli A, Mannavolo F, Stucci LS, Tucci M, Silvestris F (2017) Immune system and melanoma biology: a balance between immune surveillance and immune escape. Oncotarget 8(62): 106132-106132.

14. Pudroma X, Duoji J, Grigilavicius M, Jie D, Juzeniene A (2017) Molecular mechanisms of UVA-induced melanoma. J Environ Pathol Toxicol Oncol 36(3): 217-228.

15. Kimeswenger S, Dingelmaier HR, Foeding D, Jantschitsch C (2018) UVA1 impairs the repair of UVR-induced DNA damage in normal human melanocytes. Exp Dermatol 27(3): 276-279.

16. Ross CL, Kaushik S, Valdes RR, Anvekar R (2018) Micro RNAs in cutaneous melanoma: Role as diagnostic and prognostic biomarkers. J Cell Physiol 233(7): 5133-5141.

17. Tudej KB, Czeplelewskas E, Kozioleska WM (2017) SOX10-MITF pathway activity in melanoma cells. Arch Med Sci 13(6): 1499-1503.

18. Garman B, Anastopoulos IN, Krepler C, Brafford P, Sproesser K, et al. (2017) Genetic and genomic characterization of 462 melanoma patient-derived xenografts, tutor biopsies and cell lines. Cell Rep 21(7): 1936-1952.

19. Thyagarajan A, Shaban A, Sahu RP (2018) Micro RNA-directed cancer therapies: implications in melanoma intervention. J Pharmacol Exp Ther 364(1): 1-12.

20. Moon H, Donahue LR, Choi E, Skumpa PO, Lowry WE, et al. (2017) Melanocyte stem cell activation and translocation initiate cutaneous melanoma response to UV exposure. Cell Stem Cell 21(5): 665-678.

21. Kohler C, Wittner B, Rambow F, Radaelli E, Stanchi F, et al. (2017) Mouse cutaneous melanoma induced by mutant Braf arises from expansion and dedifferentiation of mature pigmented melanocytes. Cell Stem Cell 21(5): 679-693.